Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.03.05.21251351; this version posted March 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. A single-center retrospective cohort study of Covid-19 medications: Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon β1a and their combinations Sahand Tehrani Fateh1† , Sepand Tehrani Fateh2†, Esmaeil Salehi3, Nima Rezai4,5, Nazanin Haririan7, Abdollah Asgari3*, Amir Salehi-Najafabadi8* 1- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. 2- School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 3- M. Montazeri Hostpital, Isfahan University of Medical Sciences, Isfahan, Iran. 4- Research Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran 5- Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran 6- Science and Research Branch, Islamic Azad University, Tehran, Iran. 7- Department of Microbiology, School of Biology, University College of Science, University of Tehran, Tehran, Iran. † These authors contributed equally to this work. * Corresponding authors Email: asalehi@khayam.ut.ac.ir NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.03.05.21251351; this version posted March 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract: Many drugs have been suggested to be used for Covid-19. A suitable and efficient choice of drug would make the course of Covid-19 easier. we have investigated the efficacy of different treatment regimen in reducing hospitalization period (HP) and mortality of 324 confirmed Covid-19 patients. Received drugs included single therapy or combinations of Methylprednisolone, Remdesivir, Favipiravir, Interferon β1a, and Dexamethasone. HP and mortality were compared between different treatment groups to evaluate efficacy of each drug. HP and mortality were also calculated for patients in each treatment group based on their underlying diseases and age. we suggest that using IFN-β1a, RDV and corticosteroids might not have a significant effect on the HP or mortality of the Covid-19 patients as it was thought before. medRxiv preprint doi: https://doi.org/10.1101/2021.03.05.21251351; this version posted March 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.